NYSE · LLY
Eli Lilly and Company
$1,429.76+$56.06 (+4.08%)
Eli Lilly and Company’s quoted price is above the reported 52-week high. The range and quote may have different update times.
Loading market information…
NASDAQ · AVGR · USD
Stock price, earnings
Quote as of Feb 14, 2025, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Avinger, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.15% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Avinger, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Avinger, Inc. is a commercial-stage medical technology firm that develops, manufactures, and markets sophisticated image-guided, catheter-based systems. These devices are utilized by physicians both domestically and internationally to treat patients suffering from Peripheral Arterial Disease (PAD). Central to Avinger's offerings is its proprietary lumivascular platform. This innovative technology integrates Optical Coherence Tomography (OCT) visualization directly into interventional catheters, providing real-time, intravascular imaging to guide doctors during PAD procedures. The company's lumivascular product suite includes the Lightbox imaging consoles, as well as the Ocelot family of catheters, which are specifically designed to help physicians penetrate complete arterial blockages. Additionally, the Pantheris is an image-guided atherectomy device enabling precise removal of plaque from affected arteries. Avinger also offers its earlier-generation Chronic Total Occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2. These employ a unique rotational spinning technique, allowing physicians to switch between passive and active modes when navigating difficult CTOs. Furthermore, the company is developing IMAGE-BTK, a specialized solution for treating PAD lesions located below-the-knee. Avinger's advanced medical devices are sold to a specialized clientele, including interventional cardiologists, vascular surgeons, and interventional radiologists. The company was founded in 2007 and is headquartered in Redwood City, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:28 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2023 | Jul 27, 2023 | -$8.85-20.41% vs estimate | $2.04M-14.6% vs estimate |
|---|
| Q1 2023 | May 10, 2023 | -$10.64-44.76% vs estimate | $1.89M-16.16% vs estimate |
|---|
THE ANALYST VIEW
7 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,429.76+$56.06 (+4.08%)
Eli Lilly and Company’s quoted price is above the reported 52-week high. The range and quote may have different update times.
$0.60-$0.10 (-14.27%)
ASLAN Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 96.48% below the high.
$0.42+$0.42 (+100.0%)
CareMax, Inc.’s quoted price sits in the lower half of its reported 52-week range, 18.94% below the high.
$0.53-$0.17 (-24.12%)
Oncternal Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.04% below the high.
$2.20+$0.17 (+8.37%)
NAYA Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 87.09% below the high.
$0.03$0.00 (0.0%)
Cassava Sciences, Inc. Warrant’s quoted price sits in the lower half of its reported 52-week range, 99.73% below the high.
$0.38-$0.01 (-1.56%)
NeuBase Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.49% below the high.
$0.00$0.00 (0.0%)
G Medical Innovations Holdings Ltd’s quoted price sits in the lower half of its reported 52-week range, 99.6% below the high.
